Dr. Brimble’s NBDF-funded project aims to understand the epitope identities of T cell responses that are seen after Adeno-associated virus (AAV) gene therapy in hemophilia A and B patients. Gene therapy has the potential to provide one-time, curative, treatment for many diseases, including bleeding disorders like hemophilia. In gene therapy, engineered viruses are often used to deliver a treatment to the patient. One highly used virus is AAV. However, just like when a person encounters a virus during everyday life, the body’s immune system can defend itself from AAV treatment and react against the therapy. This happens differently in different people. It’s important to understand how different people will react to gene therapy to ensure the treatment works for whoever receives it, but right now this isn’t possible. One part of the immune system that can detect and stop a treatment from being successful is the T cell. T cells can stop Gene Therapy from working by clearing out the treated cells from the body. T cells can also help your immune system remember the therapy so that it cannot be given a second time. Each T cell has a protein on its cell surface called a ‘T cell receptor’ or TCR. These TCRs are all slightly different, and the number of possible differences is more than the number of grains of sand on earth. It’s that difference that allows the body to fight off infections you’ve never seen before. This project will try and use that difference to improve our understanding of what makes Gene Therapy succeed or fail. We aim to find TCRs that prevent Gene Therapy from working in some people. A person has around half a trillion T cells in their body. However, from 1ml of blood, we can look at 500,000 of these and capture a snapshot of what is occurring in the body. Using blood samples from hemophilia gene therapy patients, we can track what TCRs we only find after treatment is given. We can then look to see what kind of issues they caused. We aim to use this information to make decisions about how to change the design of the AAV virus for future versions of Gene therapy that would avoid having these problems from T cells.
Awarded/Presented
Tags
Career Development Award
NBDF-Sanofi
Researchers
Dr. Mark Brimble